Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985567 | 0.91 | — | — | |
| SCHEMBL1973779 | 0.80 | TSHR (0.37) | — | |
| SCHEMBL625211 | 0.80 | TDP1 (0.32) | FFAR1CPT2TDP1 | |
| SCHEMBL25385320 | 0.78 | FFAR1 (0.36) | FFAR1CPT2TDP1 | |
| SCHEMBL10758322 | 0.78 | TSHR (0.42) | FFAR1CPT2TDP1 | |
| SCHEMBL8008366 | 0.78 | FFAR1 (0.36) | FFAR1CPT2TDP1 | |
| SCHEMBL25384743 | 0.78 | TSHR (0.35) | — | |
| SCHEMBL25386399 | 0.78 | FFAR1 (0.36) | FFAR1CPT2TDP1 | |
| SCHEMBL8755240 | 0.78 | TSHR (0.42) | FFAR1CPT2TDP1 | |
| SCHEMBL22749064 | 0.78 | TSHR (0.42) | FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6410523-B1 | BONE DEFECTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1070704-A1 | VITAMIN D DERIVATIVES SUBSTITUTED AT THE 2$g(b)-POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CYP2R1, CYP24A1, VDR | FFAR1 652/4885CPT2 1328/4885TDP1 4663/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | FFAR1 240/4885CPT2 542/4885TDP1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.